Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Infinity - u may be right. Gram neg compounds farther away, though Boucher in her gram neg IDSA article characterized as "insufficient evidence" in reference to B, i.e. as in TBD. And recall the push for pathogen-specific agents... More targeted drugs getting to mkt sooner. (See article below)

That said, your posts inc come across to me as leading/loaded ... Me beginning to Q ur backstory and motives. More than just playing Devils Advocate. Maybe I'm wrong. Hope so as you come across as informed. I learn from you. Brilacidin has a lot going for it as does the larger platform even if the Fox Chase work will take more time. It can be a mini-blockbuster all on its own.

Anyway, I came across another PYMX poster that whets the appetite. Milan 2011 ECMIDD. Hopefully the April presentation on gram-neg work in Copenhagen will have updates.

In vitro activity profile of pmx-30063 against recent clinical isolates against gram + and gram - pathogens
http://files.shareholder.com/downloads/ABEA-4ITCYZ/1730124406x0x492675/7e5d6f23-496d-472b-9052-ac057a054a8d/ECCMID_2011-Gram_Pos_Neg_Activity.pdf

The value of single pathogen antibacterial agents
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012226/pdf/nihms-578161.pdf